<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Antiseizure medication maintenance therapy and drug monitoring
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Antiseizure medication maintenance therapy and drug monitoring
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Antiseizure medication maintenance therapy and drug monitoring
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Kwan, MB, BChir, FRACP, PhD, FAHMS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John-Paul Nicolo, MBBS (Hons), BMedSci, FRACP, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Garcia, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2200966147">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall approach to antiseizure medication therapy and monitoring for patients with epilepsy is reviewed here. Other aspects of epilepsy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">
          "Overview of the management of epilepsy in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2212.html" rel="external">
          "Initial treatment of epilepsy in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">
          "Seizures and epilepsy in children: Initial treatment and monitoring"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H651497458">
         <span class="h1">
          REFERRAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is usually appropriate to refer a patient with seizures to a neurologist when establishing a diagnosis and formulating a course of treatment. Referral to an epilepsy specialist may be necessary if there is doubt about the diagnosis and/or if the patient continues to have seizures.
        </p>
        <p class="headingAnchor" id="H3275879324">
         <span class="h1">
          EDUCATING PATIENTS
         </span>
        </p>
        <p class="headingAnchor" id="H181023812">
         <span class="h2">
          Epilepsy counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         For many patients, being diagnosed with epilepsy brings a time of vulnerability, uncertainty, and confusion as they wait for seizure freedom [
         <a href="#rid1">
          1
         </a>
         ]. Therefore, before starting treatment, the clinician should begin a dialogue with the patient, family, and caregivers to increase their understanding of epilepsy and their ability to report necessary and relevant information. Epilepsy affects each patient in a unique way, and patients differ in their capacity to understand various aspects of the disorder. As a result, clinicians must tailor discussions to clarify the impact of the condition on the specific patient's quality of life and expectations of the treatment plan. These discussions will improve the likelihood that the patient will comply with the plan of treatment.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SUDEP
         </strong>
         – Patients with epilepsy have a small but significant risk of sudden unexpected death in epilepsy (SUDEP). Clinicians should inform epilepsy patients, family members, and caregivers about the incidence and risk factors for SUDEP. This can be introduced as part of the rationale for recommending pharmacologic treatment in an individual diagnosed with epilepsy. SUDEP is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2215.html" rel="external">
          "Sudden unexpected death in epilepsy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other comorbidities
         </strong>
         – The treating clinician should also discuss comorbidities associated with epilepsy. The burden of comorbidity in epilepsy is high and includes several conditions such as depression, anxiety, migraine, and cardiovascular disease [
         <a href="#rid2">
          2
         </a>
         ]. Epilepsy comorbidities are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/114559.html" rel="external">
          "Comorbidities and complications of epilepsy in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alcohol and caffeine intake
         </strong>
         – Alcohol consumption in small amounts (one to two drinks per day) may not affect seizure frequency or serum levels of antiseizure medications (ASMs) in patients with well-controlled epilepsy [
         <a href="#rid3">
          3
         </a>
         ]. Heavier alcohol intake (three or more drinks per day) increases the risk of seizures, particularly during the withdrawal period (7 to 48 hours after the last drink), and this practice should be strongly discouraged [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Coffee or tea consumption is not considered harmful provided consumption of caffeine is less than 400 mg daily (around five cups of coffee) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3462903368">
         <span class="h2">
          Explaining the ASM regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinician should impress upon the patient, family, and caregivers the critical need to follow the prescribed ASM regimen. The consequences of nonadherence to ASM treatment are described in more detail below. (See
         <a class="local">
          'Nonadherence with ASM therapy'
         </a>
         below.)
        </p>
        <p>
         Written instructions on how and when to take the ASMs should be provided and should explain the dosing regimen and any potential adverse effects. The patient must also be warned not to stop taking an ASM and not to allow a prescription to run out or expire.
        </p>
        <p>
         Patients should be urged not to start any other prescription, over-the-counter medications, dietary supplements, or herbal remedies without first contacting their clinician, because these might affect serum levels of their ASMs [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H65233959">
         <span class="h1">
          ANTISEIZURE MEDICATION TITRATION
         </span>
        </p>
        <p class="headingAnchor" id="H370890921">
         <span class="h2">
          ASM selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Guidance on when to start antiseizure medication (ASM) and the initial selection of an ASM is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2212.html" rel="external">
          "Initial treatment of epilepsy in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H553591274">
         <span class="h2">
          "Start low and go slow" principle
         </span>
         <span class="headingEndMark">
          —
         </span>
         We start ASM treatment with a single drug (monotherapy). Approximately 50 percent of patients will obtain seizure freedom with the first monotherapy [
         <a href="#rid8">
          8,9
         </a>
         ]. In general, the strategy is to gradually titrate to identify the lowest effective dose to achieve seizure freedom while minimizing adverse effects. Subsequent dose adjustment is then made based on seizure control and tolerability.
        </p>
        <p>
         The benefit of slow titration is that there is a lower risk of both dose-dependent and idiosyncratic side effects [
         <a href="#rid10">
          10
         </a>
         ]. Suggested titration schedules for common ASMs are covered separately. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2212.html" rel="external">
          "Initial treatment of epilepsy in adults"
         </a>
         .)
        </p>
        <p>
         For some ASMs, such as
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         , a slow titration is mandatory to mitigate the risks of severe skin reactions [
         <a href="#rid11">
          11
         </a>
         ], particularly so when co-administered with
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         [
         <a href="#rid12">
          12
         </a>
         ]. In older adult patients, lower initial doses of ASMs and slower titration rates should be used [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H316229941">
         <span class="h2">
          Factors influencing titration rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seizure recurrence in newly diagnosed epilepsy typically occurs after three to six months [
         <a href="#rid14">
          14
         </a>
         ], permitting a slow titration. However, for patients who continue to have frequent or disabling seizures after epilepsy onset, a medication that can be safely titrated rapidly may be preferred over one requiring weeks or months to achieve a therapeutic dose. Such medications include
         <a class="drug drug_general" data-topicid="106990" href="/z/d/drug information/106990.html" rel="external">
          brivaracetam
         </a>
         ,
         <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">
          lacosamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         , and
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1023439682">
         <span class="h2">
          Target dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is relatively little evidence to guide which initial ASM dose should be targeted in the absence of dose-dependent side effects, although observations from cohort studies suggest the majority of patients obtaining seizure freedom with a specific medication usually do so at low to medium doses, for example 1500 mg/day for
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         , 300 mg/day for
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         , and 400 mg/day for
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         [
         <a href="#rid8">
          8
         </a>
         ]. Details regarding the recommended initial dose for individual ASMs and a potential titration schedule are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3419118353">
         <span class="h2">
          Risk of seizures during titration phase
         </span>
         <span class="headingEndMark">
          —
         </span>
         If a seizure occurs very soon after the target dose of a specific ASM is reached, a question sometimes arises as to whether this constitutes treatment failure and necessitates a treatment change, whether it be dose escalation or a new ASM.
        </p>
        <p>
        </p>
        <p>
         Addressing this question requires consideration of pharmacokinetic and pharmacodynamic properties of the specific medication chosen  (
         <a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">
          table 1
         </a>
         ). ASMs with long half-lives require more time to come up to steady state, at which time a seizure would indicate treatment failure. As an example, for
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         , peak serum levels occur 1.3 hours after dosing and steady-state levels within 24 to 48 hours [
         <a href="#rid16">
          16
         </a>
         ], indicating seizures occurring beyond this time frame may be considered a treatment failure.
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          Lamotrigine
         </a>
         , by comparison, has a longer half-life of 25 hours [
         <a href="#rid17">
          17
         </a>
         ], and at least four to five days of treatment at the target dose would be expected prior to considering the treatment to be therapeutic. Any decision requires careful consideration of patient-specific factors such as the clinical impact of seizures, urgency to obtain seizure freedom (for example, relating to occupational or driving restrictions), or an expressed desire that the lowest possible efficacious dose be established.
        </p>
        <p class="headingAnchor" id="H2647766202">
         <span class="h1">
          MONITORING
         </span>
        </p>
        <p class="headingAnchor" id="H2618170773">
         <span class="h2">
          Follow-up visits
         </span>
         <span class="headingEndMark">
          —
         </span>
         We monitor epilepsy treatment regularly: generally every one to three months for patients recently started on treatment or with suboptimal seizure control, and every six to 12 months for patients with chronic stable epilepsy. Follow-up visits should be scheduled to record seizure frequency, inquire about medication side effects, and obtain any needed tests [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Laboratory studies (eg, blood counts, hepatic and renal function, and antiseizure medication [ASM] levels) can be obtained when indicated. These visits are also used to address concerns the patient may have about taking the medication and psychosocial aspects of their disorder.
        </p>
        <p class="headingAnchor" id="H222113541">
         <span class="h2">
          Seizure calendar
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients and family members should be encouraged to record seizures in a diary or calendar, which can be brought to medical appointments for review. Electronic seizure diaries are also available [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefits
         </strong>
         – There are several benefits to using seizure calendars. They may be used to track the patient's response to ASM therapy, including possible side effects. Seizure calendars can help identify seizure triggers. In one study of 71 patients completing daily seizure diaries, both lack of sleep and higher self-reported stress and anxiety were associated with seizure occurrence [
         <a href="#rid20">
          20
         </a>
         ]. Seizures were also associated with the patients' own prediction of the likelihood of seizure occurrence. Other reported seizure triggers include visual, olfactory, and auditory stimuli; alcohol consumption; missed meals; and hormone fluctuations related to the menstrual cycle [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Accuracy and unawareness of seizures
         </strong>
         – While information from seizure diaries is vital to guide ASM treatment, all diaries are dependent on accurate recognition and recording of seizures [
         <a href="#rid22">
          22
         </a>
         ]. Studies involving inpatient video-electroencephalography (EEG) monitoring [
         <a href="#rid22">
          22
         </a>
         ] and implanted seizure advisory systems [
         <a href="#rid23">
          23
         </a>
         ] have consistently reported high levels of seizure unawareness, and patients or caregivers also report false-positive events that are not seizures. Other potential problems, such as compliance with diary maintenance, may be partially overcome by the use of electronic seizure diaries [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1435861465">
         <span class="h2">
          ASM levels
         </span>
        </p>
        <p class="headingAnchor" id="H3930219010">
         <span class="h3">
          Indications for monitoring ASM levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several well-established indications for monitoring serum ASM levels (ie, concentrations), as follows [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To establish an individual therapeutic concentration (level) that can be used at subsequent times to assess potential causes for a change in drug response (see
         <a class="local">
          'Individual therapeutic concentration'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As an aid in the diagnosis of clinical toxicity
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To assess compliance, particularly in patients with uncontrolled seizures or breakthrough seizures (see
         <a class="local">
          'Breakthrough seizures'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To guide dose adjustment in situations associated with increased pharmacokinetic variability (eg, in children, older adults, patients with associated diseases, drug formulation changes)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When a potentially important pharmacokinetic change is anticipated (eg, in pregnancy, or when an interacting drug is added or removed)
        </p>
        <p>
        </p>
        <p>
         Given the changes in volume of distribution and the increased renal clearance and hepatic metabolism of ASMs associated with pregnancy, serum levels of ASMs should be followed at regular intervals during pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">
          "Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Antiseizure medication monitoring and dose adjustment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3305263844">
         <span class="h3">
          Trough levels and free levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         Standardized sampling time is important [
         <a href="#rid24">
          24
         </a>
         ]. Ideally, serum levels should be collected immediately before the next dose (a trough level) to measure the lowest ASM concentration in an individual, particularly for ASMs with short half-lives such as
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         . Trough levels are used to determine the therapeutic ASM concentration (see
         <a class="local">
          'Individual therapeutic concentration'
         </a>
         below) and for guiding dose adjustments.
        </p>
        <p>
         Measuring free (unbound) levels of ASMs can be clinically useful when treating with ASMs that are highly protein bound, such as
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         and
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Note that clinical treatment decisions should not be made based on ASM levels alone without relevant consideration of patient history and clinical symptoms.
        </p>
        <p class="headingAnchor" id="H27539577">
         <span class="h3">
          Individual therapeutic concentration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The "individual therapeutic concentration" is defined as the ASM level, or range of levels, empirically associated with an optimum response in an individual patient [
         <a href="#rid24">
          24
         </a>
         ]. Overall, establishing the individual therapeutic concentration is more clinically useful than the laboratory reference range given the considerable interpatient variability in the concentration of a medication that produces a therapeutic response [
         <a href="#rid26">
          26
         </a>
         ]. This concept applies to both older and newer ASMs.
        </p>
        <p class="headingAnchor" id="H2359696251">
         <span class="h3">
          Utility for older versus newer ASMs
         </span>
         <span class="headingEndMark">
          —
         </span>
         As a general principle, the role of measuring levels to guide adjustments of doses is best established for older medications with dose-dependent pharmacokinetics, particularly
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         [
         <a href="#rid24">
          24
         </a>
         ]. Newer-generation ASMs may exhibit significant pharmacokinetic variability at any age [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2078242988">
         <span class="h3">
          Evidence from trials
         </span>
         <span class="headingEndMark">
          —
         </span>
         Randomized trials have failed to demonstrate a benefit of therapeutic drug monitoring with respect to seizure outcomes [
         <a href="#rid28">
          28,29
         </a>
         ]. A randomized trial of therapeutic monitoring for dose adjustment of various newer-generation ASMs (
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         ,
         <a class="drug drug_general" data-topicid="106990" href="/z/d/drug information/106990.html" rel="external">
          brivaracetam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">
          zonisamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ) randomly assigned 151 patients in a 1:1 ratio to a systematic drug monitoring group, with ASM levels available at each appointment, or to a rescue drug monitoring group, with ASM levels available for lack of ASM efficacy or adverse events [
         <a href="#rid30">
          30
         </a>
         ]. There was no difference between the two groups for the outcomes of ASM treatment efficacy or tolerability. The authors concluded that systematic level monitoring of newer ASMs was not beneficial due to a poor correlation between clinical effects and drug levels [
         <a href="#rid30">
          30
         </a>
         ]. This is consistent with the results of an observational study, which found that plasma levels of ASMs were lower in seizure-free patients than in those with ongoing seizures, suggesting that efficacy can be reached at the lower part or at times even below the reference ranges in patients with drug-responsive epilepsy [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2378268870">
         <span class="h3">
          Selected ASMs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The usefulness of measuring levels of specific ASM is discussed for several commonly prescribed ASMs:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phenytoin
         </strong>
         – Therapeutic monitoring of
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         is important because of its narrow therapeutic index and the unpredictable relationship between dose and therapeutic level [
         <a href="#rid24">
          24
         </a>
         ], due to a variety of factors including variable absorption, protein binding, and drug interactions [
         <a href="#rid32">
          32
         </a>
         ]. Because of its nonlinear pharmacokinetics, small increments in dose can produce large changes in serum levels. While most patients attain seizure control at levels of 10 to 20 mg/L (40 to 79 micromol/L) some patients may require only very low levels and others will obtain a benefit from levels above 20 mg/L without developing dose-dependent side effects [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Levetiracetam
         </strong>
         – Studies have shown that those taking therapeutic doses of
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         have levels in the order of 12 to 46 mg/L (70 to 270 micromol/L). However, a role for therapeutic monitoring of levetiracetam levels to guide dosing has not been established [
         <a href="#rid33">
          33
         </a>
         ], with the exception of during pregnancy [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Valproate
         </strong>
         – Several studies have examined the efficacy of
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         with reference to drug levels. Collectively, seizure freedom is generally established at levels between 50 and 100 mg/L (346 and 693 micromol/L) [
         <a href="#rid35">
          35-38
         </a>
         ]. A higher level may be maintained if needed for better seizure control, provided dose-related adverse effects are not present. In the absence of adverse effects, the dose can be increased to achieve better seizure control without checking levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lamotrigine
         </strong>
         – There does not appear to be a clear relationship between
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         levels and clinical response [
         <a href="#rid39">
          39,40
         </a>
         ]. Adverse effects are more common in levels above 10 mg/L, although much higher levels (above 20 mg/L) are often tolerated and can yield additional benefit in patients with difficult-to-control epilepsy [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carbamazepine
         </strong>
         – The optimal effect of
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         treatment is generally achieved at concentrations of 4 to 12 mg/L (17 to 51 micromol/L) [
         <a href="#rid42">
          42,43
         </a>
         ], although symptoms of carbamazepine toxicity can be seen at similar concentrations to those associated with optimal seizure control [
         <a href="#rid44">
          44
         </a>
         ]. Lower concentrations may be associated with symptoms of toxicity in the setting of combination therapy, particularly so with
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         due to the pharmacodynamic interaction [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3508695961">
         <span class="h2">
          Role of seizure monitoring devices
         </span>
         <span class="headingEndMark">
          —
         </span>
         Existing seizure monitoring devices measure a combination of accelerometry, surface electromyographic (EMG) signals, electrodermal activity (EDA), heart rate, and heart rate variability. More studies are required to explore parameters that do not require motion for seizure detection. Several wearable devices are approved by the US Food and Drug Administration (FDA) and/or have received European CE (conformité européenne) certification for the detection of generalized tonic-clonic seizures [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         A 2022 systematic review and meta-analysis of automated seizure detection with noninvasive wearable devices found that devices had a high sensitivity for detecting tonic-clonic seizures during recording time in a video-EEG setting but that false alarm rates were relatively high [
         <a href="#rid46">
          46
         </a>
         ]. Wearable devices have also shown promise in their ability to differentiate between epileptic and psychogenic seizures [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Ultra-long-term EEG recording via a subcutaneous device may have a role in seizure forecasting and detection [
         <a href="#rid48">
          48,49
         </a>
         ]; however, utilization is mainly restricted to the research setting.
        </p>
        <p class="headingAnchor" id="H3280581911">
         <span class="h1">
          NONADHERENCE WITH ASM THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H794185009">
         <span class="h2">
          Prevalence and consequences
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies have consistently shown high rates of medication nonadherence among people with epilepsy, ranging from 26 to 79 percent [
         <a href="#rid50">
          50-54
         </a>
         ].
        </p>
        <p>
         The potential consequences of antiseizure medication (ASM) nonadherence are well established. The RANSOM (Research on Antiepileptic Nonadherence and Serious Outcomes in Medicaid) study of more than 30,000 epilepsy patients found that nonadherence was associated with a more than threefold risk of mortality compared with adherence (hazard ratio [HR] = 3.32) [
         <a href="#rid55">
          55
         </a>
         ]. Other consequences include a higher incidence of attendance to emergency departments, hospital admissions, fractures, head injuries, and increased health care costs [
         <a href="#rid52">
          52,53,55
         </a>
         ]. Another study in which nonadherence was identified by therapeutic drug monitoring with reference to the patient's own control value [
         <a href="#rid56">
          56
         </a>
         ] found that adherence was a factor in 39 percent of patients admitted to hospital with seizures.
        </p>
        <p class="headingAnchor" id="H2505695651">
         <span class="h2">
          Reasons and possible risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A report of 200 people with epilepsy found that female sex and older age were associated with a lower risk of ASM nonadherence, while reduced resilience and symptoms of anxiety and depression were associated with an increased risk [
         <a href="#rid57">
          57
         </a>
         ]. A retrospective cohort study from the United States of people with newly treated epilepsy used Medicare beneficiary data and identified several factors associated with increased risk of nonadherence, including Black race and geographic region [
         <a href="#rid58">
          58
         </a>
         ]. Factors associated with a lower risk of nonadherence included older age, female sex, and neurologist visit.
        </p>
        <p>
         Nonadherence can be intentional and/or unintentional (eg, forgetting to take a dose or mistakenly taking an incorrect dose) [
         <a href="#rid59">
          59
         </a>
         ]. In one study of adherence conducted by online survey, 40 percent of people with epilepsy reported unintentional nonadherence and 30 percent intentional nonadherence [
         <a href="#rid59">
          59
         </a>
         ]. In this study, factors associated with unintentional nonadherence included feeling depressed (odds ratio [OR] 1.410), younger age (OR 1.448), and memory problems (OR 1.529). Those with intentional nonadherence cite adverse effects, either experienced or theoretical, and perceived lack of efficacy as the reasons for their decision. Neither intentional nor unintentional nonadherence were associated with polytherapy or seizure freedom.
        </p>
        <p>
         Discrepancies between prescribed treatment and treatment taken may also be attributable to miscommunication between the treating clinician and patient [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         Patient-initiated discontinuation may be considered the most extreme form of nonadherence. In a study conducted in Australia, a high-income country, 16 percent of patients with newly diagnosed and treated epilepsy self-discontinued treatment after a median duration of 1.4 years, with a median period of seizure freedom of less than a year [
         <a href="#rid61">
          61
         </a>
         ]. The most common reasons for discontinuation were the presence of adverse effects, belief that treatment was no longer necessary, pregnancy-related concerns, or the culmination of chronic nonadherence. Concerningly, 65 percent experienced further seizures after discontinuation of therapy. Overall, 55 percent restarted treatment, sometimes after a significant seizure-related injury. Those who had stopped treatment due to side effects were most at risk of seizure recurrence. These findings highlight areas for improved discussion with patients, including the chronicity of epilepsy and management strategies for current or potential adverse effects.
        </p>
        <p>
         Epilepsy classification may also affect adherence, with nonadherence higher in those with generalized seizures compared with focal seizures in one study [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1210074540">
         <span class="h2">
          Strategies for improving adherence
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to patient education, we employ the use of calendars, medication alarms, or dosette boxes to improve medication adherence. Various studies, including randomized trials, have looked at the role of interventions to improve adherence to ASMs. The studied methods include both educational and behavioral interventions [
         <a href="#rid62">
          62
         </a>
         ]. A randomized trial combined the use of motivational interviewing with provision of calendars for participants to self-monitor their medication-taking behavior. Two-hundred-and-seventy-five participants were studied, with several different outcome measures. Compared with the controls, those in the intervention group performed better in measures of medication adherence, therapeutic drug levels, reduced medication concerns, social cognitive variables, seizure severity, and health-related quality of life [
         <a href="#rid63">
          63
         </a>
         ]. Overall, behavioral interventions, such as the use of intensive reminders, have provided more favorable effects on adherence than educational interventions [
         <a href="#rid63">
          63-65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3419044412">
         <span class="h1">
          BREAKTHROUGH SEIZURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with breakthrough seizures or failure of initial antiseizure medication (ASM) monotherapy that is adequately dosed and tolerated, there is only one decision to make, which is to either change to an alternative ASM or to add a second ASM. In practice, ASM addition (combination therapy) is appropriate if the first ASM is well tolerated and improves but does not abolish seizures, whereas ASM substitution is appropriate if the first ASM is poorly tolerated at a lower dose or fails to improve seizure control [
         <a href="#rid66">
          66
         </a>
         ]. The same principles apply to the management of those with established drug-resistant epilepsy.
        </p>
        <p>
         Although data from randomized trials are limited, several studies have found similar seizure outcomes when switching ASM monotherapy (substitution) was compared with adding a second ASM [
         <a href="#rid9">
          9,67,68
         </a>
         ]. As examples, an open-label randomized trial of 157 patients with focal epilepsy not controlled on a single ASM found that the 12-month probability of seizure freedom was similar for alternative monotherapy versus polytherapy (14 versus 16 percent) [
         <a href="#rid67">
          67
         </a>
         ]. A longitudinal observational study of 489 patients treated between 1982 and 2012 after failure of the initial ASM monotherapy demonstrated that more patients were treated with combination therapy compared with sequential monotherapy (69 versus 31 percent), although seizure-free rates were similar for those with substitution monotherapy versus combination therapy (20 versus 21 percent, risk ratio 1.17) [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         An earlier prospective study of patients with inadequate seizure control on the first well-tolerated ASM also found that the rates of seizure freedom were similar for the substituted monotherapy and add-on therapy groups (17 versus 26 percent) [
         <a href="#rid9">
          9
         </a>
         ]. A study of 816 ASM changes in 436 adult patients with drug-resistant epilepsy showed no difference between ASM addition or substitution in seizure outcome or tolerability measures [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1795944714">
         <span class="h1">
          GENERIC SUBSTITUTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most generic medications are much less expensive than brand-name products, which motivates the substitution of generic antiseizure medications (ASMs) for branded ASMs [
         <a href="#rid70">
          70,71
         </a>
         ]. The bioequivalence of generic ASMs and their potential clinical effect are reviewed in the sections that follow.
        </p>
        <p class="headingAnchor" id="H2338184174">
         <span class="h2">
          Bioequivalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         According to the FDA, generic drugs must be "identical, or bioequivalent, to a brand-name drug in terms of dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use" [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
         Measures used to determine bioequivalence include  (
         <a class="graphic graphic_figure graphicRef142821" href="/z/d/graphic/142821.html" rel="external">
          figure 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The area under the concentration-time curve (AUC) of drug concentration in plasma (plotted on the y-axis) versus time after dose (plotted on the x-axis), which quantifies the exposure to a drug and its clearance rate from the body
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The peak concentration (Cmax) of drug in the blood after a dose is given
        </p>
        <p>
        </p>
        <p>
         For products to be considered bioequivalent according to FDA and European regulations, the geometric means of the AUC and Cmax ratios between the generic and the branded product and their corresponding 90 percent confidence intervals should fall within the 80 to 125 percent range [
         <a href="#rid73">
          73-75
         </a>
         ].
        </p>
        <p>
         The EQUIGEN (Equivalence Among Antiepileptic Drug Generic and Brand Products in People with Epilepsy) randomized trial demonstrated evidence of bioequivalence of three disparate
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         products [
         <a href="#rid76">
          76
         </a>
         ]. The same conclusion was drawn in a population of so-called "generic-brittle" patients with refractory epilepsy or a history of seizures occurring in the setting of brand switching [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3269409273">
         <span class="h2">
          Acceptance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surveys have shown that a significant proportion of people with epilepsy and their caregivers are concerned about adverse effects and/or increased seizure frequency after a generic substitution [
         <a href="#rid78">
          78
         </a>
         ]. A Canadian study showed that the rate of switching back from a generic ASM product to a brand-name product was higher than for comparable medications such as antidepressants [
         <a href="#rid79">
          79
         </a>
         ], possibly reflecting a poor acceptance of generic compounds. There is also retrospective evidence that medication adherence is worse in those taking generic formulations, as they may be perceived by patients to be inferior products [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         Surveyed neurologists, however, generally accept the use of generic ASMs [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
         In the United States as of 2016, generic medications (including but not limited to ASMs) accounted for 89.5 percent of all dispensed medications but for only 25.8 percent of pharmaceutical expenditures [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3541458098">
         <span class="h2">
          Effect on seizures and safety
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the accumulating evidence regarding the safety and efficacy of generic ASM formulations, we agree with a 2016 position statement from the American Epilepsy Society, which notes that "drug formulation substitution with FDA-approved generic products reduces cost without compromising efficacy" [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizure control
         </strong>
         – Although data are limited, the highest-quality evidence comes from a 2010 meta-analysis and systematic review, which included seven randomized trials and 204 patients; there was no difference in the odds of uncontrolled seizure for patients taking generic ASMs compared with those taking brand-name ASMs [
         <a href="#rid83">
          83
         </a>
         ]. A retrospective German study of 678 children and adolescents with epilepsy divided the cohort into a group with seizure recurrence (n = 339) and a group of seizure-free controls (n = 339) [
         <a href="#rid84">
          84
         </a>
         ]. The risk of seizure recurrence was not associated with a switch in brand name or generic ASMs; a switch in treatment occurred for only 11 percent of seizure cases compared with 25 percent of controls [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nevertheless, several case-control studies have shown a possible effect of generic substitution on the risk of requiring emergency or hospital-based treatment for epilepsy [
         <a href="#rid85">
          85-87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effect on ASM levels
         </strong>
         – Variation in ASM serum levels could lead to increased seizures or toxicity in some patients, but data are limited and inconclusive. A study of 50 patients with breakthrough seizures after switching to a generic ASM found lower ASM levels at the time of the breakthrough seizure in 21 of 26 patients with known levels before and after generic substitution [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, a retrospective analysis assessed intrasubject variation in plasma concentration of three ASMs (
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         , and
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         ) after generic substitution compared with a control group that continued using the brand-name formulation [
         <a href="#rid89">
          89
         </a>
         ]. While both groups exhibited very large day-to-day variability in plasma levels, the proportion of patients exhibiting a change in concentration greater than -20 or +20 percent was similar for the generic substitution compared with the control group for lamotrigine (22 versus 33 percent) and levetiracetam (44 versus 38 percent), and higher in the control (brand-name) group for topiramate (41 versus 6 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          The refilling effect
         </strong>
         – An important caveat in interpreting the occurrence of seizures in the setting of medication substitution is that refilling of ASM prescriptions is associated with an increased risk of breakthrough seizures, irrespective of whether the refilling occurs with a brand-name or generic product [
         <a href="#rid90">
          90
         </a>
         ]. This is supported by a large population-based case-crossover study of more than 83,000 patients, which found that refilling with the same ASM was associated with an increased risk of breakthrough seizures but that there was no additional risk associated with changing to a different product [
         <a href="#rid91">
          91
         </a>
         ]. This effect may occur because refilling often takes place when patients are running out of medications, leading to missed doses or temporary dose reduction by the patient.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11812599">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113971.html" rel="external">
          "Society guideline links: Seizures and epilepsy in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/113981.html" rel="external">
          "Society guideline links: Seizures and epilepsy in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3524660677">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Education
         </strong>
         – The diagnosis of epilepsy can be distressing. Before starting treatment, clinicians should begin a dialogue with the patient, family, and caregivers to increase their understanding of epilepsy and their ability to report necessary and relevant information. The discussion should review the incidence and risk factors for sudden unexpected death in epilepsy (SUDEP), other epilepsy comorbidities, and expectations of the treatment plan, including the importance of adherence to antiseizure medication (ASM) therapy. (See
         <a class="local">
          'Educating patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ASM titration
         </strong>
         – We start treatment with a single ASM (monotherapy). Approximately 50 percent of patients will obtain seizure freedom with the first monotherapy. In general, the strategy is to "start low and go slow" by gradually titrating to the lowest effective dose that achieves seizure freedom while minimizing adverse effects. However, for patients who continue to have frequent or disabling seizures after epilepsy onset, a medication that can be safely titrated rapidly may be preferred. (See
         <a class="local">
          'Antiseizure medication titration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – We monitor patients with epilepsy with routine follow-up visits to record seizure frequency, inquire about medication side effects, and obtain any needed tests. We encourage the use of a seizure calendar to help track the patient's response to ASM therapy and identify possible side effects and seizure triggers. (See
         <a class="local">
          'Follow-up visits'
         </a>
         above and
         <a class="local">
          'Seizure calendar'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ASM levels
         </strong>
         – Indications for monitoring serum ASM levels include determining the individual therapeutic concentration (level), diagnosing ASM toxicity, assessing adherence, and guiding dose adjustments in selected clinical situations. ASM serum levels should be collected immediately before the next dose (a trough level) to measure the lowest ASM concentration, which is used to determine the individual therapeutic ASM concentration. (See
         <a class="local">
          'Indications for monitoring ASM levels'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The usefulness of measuring levels for selected ASMs is discussed above for
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         . (See
         <a class="local">
          'Selected ASMs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonadherence
         </strong>
         – Rates of nonadherence are high among people with epilepsy. The potential consequences include an increased risk of seizures, hospitalization, fractures, head injuries, and mortality. Factors associated with an increased risk of nonadherence include younger age, feeling depressed, ASM adverse effects, perceived lack of efficacy, and belief that treatment was no longer needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to patient education, the use of calendars, medication alarms, and medication dosette boxes may help improve adherence. (See
         <a class="local">
          'Nonadherence with ASM therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Breakthrough seizures
         </strong>
         – For patients with breakthrough seizures or failure of initial ASM monotherapy that is adequately dosed and tolerated, adding a second ASM (combination therapy) is appropriate if the first ASM is well tolerated and improves but does not abolish seizures; ASM substitution is appropriate if the first ASM is poorly tolerated at a lower dose or fails to improve seizure control. Although data from randomized trials are limited, several studies have found similar seizure outcomes when switching ASM monotherapy was compared with adding a second ASM. (See
         <a class="local">
          'Breakthrough seizures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Generic substitution
         </strong>
         – Most generic medications are much less expensive than brand-name products. Bioequivalence of generic medications is defined by regulatory authorities. Although patient acceptance of (and adherence to) generic ASM therapy may be lower compared with brand-name ASMs, accumulating evidence suggests that the use of generic ASMs does not compromise efficacy. (See
         <a class="local">
          'Generic substitution'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Reeder S, Foster E, Vishwanath S, Kwan P. Experience of waiting for seizure freedom and perception of machine learning technologies to support treatment decision: A qualitative study in adults with recent onset epilepsy. Epilepsy Res 2023; 190:107096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol 2016; 15:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001; 42:1266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hauser WA, Ng SK, Brust JC. Alcohol, seizures, and epilepsy. Epilepsia 1988; 29 Suppl 2:S66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asadi-Pooya AA, Zeraatpisheh Z, Rostaminejad M, Damabi NM. Caffeinated drinks, fruit juices, and epilepsy: A systematic review. Acta Neurol Scand 2022; 145:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gidal BE, French JA, Grossman P, Le Teuff G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 2009; 72:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaiboriboon K, Guevara M, Alldredge BK. Understanding herb and dietary supplement use in patients with epilepsy. Epilepsia 2009; 50:1927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000; 9:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011; 10:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998; 18:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch LJ, Weintraub DB, Buchsbaum R, et al. Predictors of Lamotrigine-associated rash. Epilepsia 2006; 47:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vu LC, Piccenna L, Kwan P, O'Brien TJ. New-onset epilepsy in the elderly. Br J Clin Pharmacol 2018; 84:2208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology 1991; 41:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seiden LG, Connor GS. The importance of drug titration in the management of patients with epilepsy. Epilepsy Behav 2022; 128:108517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004; 43:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messenheimer JA. Lamotrigine. Epilepsia 1995; 36 Suppl 2:S87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fountain NB, Van Ness PC, Swain-Eng R, et al. Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology 2011; 76:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher RS. Tracking epilepsy with an electronic diary. Acta Paediatr 2010; 99:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haut SR, Hall CB, Masur J, Lipton RB. Seizure occurrence: precipitants and prediction. Neurology 2007; 69:1905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dionisio J, Tatum WO 4th. Triggers and techniques in termination of partial seizures. Epilepsy Behav 2010; 17:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher RS, Blum DE, DiVentura B, et al. Seizure diaries for clinical research and practice: limitations and future prospects. Epilepsy Behav 2012; 24:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook MJ, O'Brien TJ, Berkovic SF, et al. Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study. Lancet Neurol 2013; 12:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perucca E. Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies. Clin Pharmacokinet 1984; 9 Suppl 1:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet 2013; 52:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jannuzzi G, Cian P, Fattore C, et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. Epilepsia 2000; 41:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Roubaie Z, Guadagno E, Ramanakumar AV, et al. Clinical utility of therapeutic drug monitoring of antiepileptic drugs: Systematic review. Neurol Clin Pract 2020; 10:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aícua-Rapún I, André P, Rossetti AO, et al. Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment. Ann Neurol 2020; 87:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aícua-Rapún I, André P, Rossetti AO, et al. Seizure freedom and plasma levels of newer generation antiseizure medications. Acta Neurol Scand 2021; 144:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979; 4:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leppik IE, Rarick JO, Walczak TS, et al. Effective levetiracetam doses and serum concentrations: age effects. Epilepsia 2002; 43:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomson T, Palm R, Källén K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 2007; 48:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gram L, Flachs H, Würtz-Jørgensen A, et al. Sodium valproate, serum level and clinical effect in epilepsy: a controlled study. Epilepsia 1979; 20:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate - a 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scand 1982; 65:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neels HM, Sierens AC, Naelaerts K, et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004; 42:1228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundqvist A, Tomson T, Lundkvist B. Pharmacokinetics of valproic acid in patients with juvenile myoclonic epilepsy on monotherapy. Ther Drug Monit 1997; 19:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartoli A, Guerrini R, Belmonte A, et al. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 1997; 19:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besag FM, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch LJ, Weintraub D, Du Y, et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004; 63:1022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005; 64:1868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li W, Wang G, Lei X, et al. Seizure detection based on wearable devices: A review of device, mechanism, and algorithm. Acta Neurol Scand 2022; 146:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naganur V, Sivathamboo S, Chen Z, et al. Automated seizure detection with noninvasive wearable devices: A systematic review and meta-analysis. Epilepsia 2022; 63:1930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naganur VD, Kusmakar S, Chen Z, et al. The utility of an automated and ambulatory device for detecting and differentiating epileptic and psychogenic non-epileptic seizures. Epilepsia Open 2019; 4:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duun-Henriksen J, Baud M, Richardson MP, et al. A new era in electroencephalographic monitoring? Subscalp devices for ultra-long-term recordings. Epilepsia 2020; 61:1805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brinkmann B, Nurse E, Nasseri M, et al. Seizure forecasting and detection with wearable devices and subcutaneous EEG-A practical seizure gauge. Neurology 2022; 98:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang C, Hao Z, Yu D, et al. The prevalence rates of medication adherence and factors influencing adherence to antiepileptic drugs in children with epilepsy: A systematic review and meta analysis. Epilepsy Res 2018; 142:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malek N, Heath CA, Greene J. A review of medication adherence in people with epilepsy. Acta Neurol Scand 2017; 135:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ettinger AB, Manjunath R, Candrilli SD, Davis KL. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav 2009; 14:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 2008; 49:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faught E, Duh MS, Weiner JR, et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology 2008; 71:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samsonsen C, Reimers A, Bråthen G, et al. Nonadherence to treatment causing acute hospitalizations in people with epilepsy: an observational, prospective study. Epilepsia 2014; 55:e125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narducci F, Lanzone J, Ricci L, et al. Determinants of medication adherence in people with epilepsy: A multicenter, cross-sectional survey. Epilepsy Behav 2023; 138:109029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terman SW, Kerr WT, Marcum ZA, et al. Antiseizure medication adherence trajectories in Medicare beneficiaries with newly treated epilepsy. Epilepsia 2021; 62:2778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henning O, Johannessen Landmark C, Nakken KO, Lossius MI. Nonadherence to treatment regimens in epilepsy from the patient's perspective and predisposing factors: Differences between intentional and unintentional lack of adherence. Epilepsia 2019; 60:e58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mevaag M, Henning O, Baftiu A, et al. Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs. Acta Neurol Scand 2017; 135:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma S, Chen Z, Rychkova M, et al. Risk factors and consequences of self-discontinuation of treatment by patients with newly diagnosed epilepsy. Epilepsy Behav 2022; 131:108664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Aqeel S, Gershuni O, Al-Sabhan J, Hiligsmann M. Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. Cochrane Database Syst Rev 2020; 10:CD008312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pakpour AH, Gholami M, Esmaeili R, et al. A randomized controlled multimodal behavioral intervention trial for improving antiepileptic drug adherence. Epilepsy Behav 2015; 52:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown I, Sheeran P, Reuber M. Enhancing antiepileptic drug adherence: a randomized controlled trial. Epilepsy Behav 2009; 16:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiIorio C, Reisinger EL, Yeager KA, McCarty F. A telephone-based self-management program for people with epilepsy. Epilepsy Behav 2009; 14:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58:S2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003; 57:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hakeem H, Alsfouk BAA, Kwan P, et al. Should substitution monotherapy or combination therapy be used after failure of the first antiseizure medication? Observations from a 30-year cohort study. Epilepsia 2023; 64:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janmohamed M, Lawn N, Spilsbury K, et al. Starting a new anti-seizure medication in drug-resistant epilepsy: Add-on or substitute? Epilepsia 2021; 62:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vossler DG, Anderson GD, Bainbridge J. AES Position Statement on Generic Substitution of Antiepileptic Drugs. Epilepsy Curr 2016; 16:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Straka RJ, Keohane DJ, Liu LZ. Potential Clinical and Economic Impact of Switching Branded Medications to Generics. Am J Ther 2017; 24:e278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesser RP, Krauss G. Buy some today: can generics be safely substituted for brand-name drugs? Neurology 2001; 57:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odi R, Franco V, Perucca E, Bialer M. Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe. Epilepsia 2021; 62:285.
          </a>
         </li>
         <li class="breakAll">
          Committee for medicinal products for human use (CHMP). Guideline on the investigation of bioequivalence. European Medicines Agency 2010. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf (Accessed on July 20, 2023).
         </li>
         <li class="breakAll">
          Guidance for Industry. Statistical Approaches to Establishing Bioequivalence. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). January 2001. https://www.fda.gov/media/70958/download (Accessed on July 20, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg M, Welty TE, Gidal BE, et al. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. JAMA Neurol 2017; 74:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ting TY, Jiang W, Lionberger R, et al. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard. Epilepsia 2015; 56:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsson P, Pearson K, Reimers A, Källén K. Widespread skeptic attitudes among people with epilepsy toward generic antiseizure drugs - A Swedish survey study. Epilepsy Behav 2021; 114:107554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007; 48:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gollwitzer S, Kostev K, Hagge M, et al. Nonadherence to antiepileptic drugs in Germany: A retrospective, population-based study. Neurology 2016; 87:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsson P, Freij J, Compagno Strandberg M, et al. Physicians' attitudes toward generic substitutions of antiseizure drugs in epilepsy. Acta Neurol Scand 2021; 144:600.
          </a>
         </li>
         <li class="breakAll">
          Medicines Use and Spending in the U.S. A Review of 2016 and Outlook to 2021. IQVIA Institute for Human Data Science https://www.iqvia.com/insights/the-iqvia-institute/reports/medicines-use-and-spending-in-the-us-a-review-of-2016 (Accessed on July 14, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010; 70:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang JD, Kostev K, Reindl C, et al. Manufacturer switch of anti-seizure drugs may not increase the risk of seizure recurrence in Children: A nationwide study of prescription data in Germany. Epilepsy Behav 2021; 115:107705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zachry WM 3rd, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009; 50:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen RN, Campbell JD, Sullivan SD. Association between antiepileptic drug switching and epilepsy-related events. Epilepsy Behav 2009; 15:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rascati KL, Richards KM, Johnsrud MT, Mann TA. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy 2009; 29:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg MJ, Gross RA, Tomaszewski KJ, et al. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008; 71:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Contin M, Alberghini L, Candela C, et al. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens. Epilepsy Res 2016; 122:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther 2010; 88:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kesselheim AS, Bykov K, Gagne JJ, et al. Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study. Neurology 2016; 87:1796.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 141678 Version 2.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36738538" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Experience of waiting for seizure freedom and perception of machine learning technologies to support treatment decision: A qualitative study in adults with recent onset epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26549780" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Comorbidities of epilepsy: current concepts and future perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11737161" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3168960" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Alcohol, seizures, and epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34694642" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Caffeinated drinks, fruit juices, and epilepsy: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19188572" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Assessment of potential drug interactions in patients with epilepsy: impact of age and sex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19486356" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Understanding herb and dietary supplement use in patients with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11737159" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effectiveness of first antiepileptic drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11034869" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Epilepsy after the first drug fails: substitution or add-on?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21511198" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The pharmacological treatment of epilepsy in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9565739" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Safety review of adult clinical trial experience with lamotrigine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16499755" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Predictors of Lamotrigine-associated rash.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29856080" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : New-onset epilepsy in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2067659" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The risk of seizure recurrence following a first unprovoked seizure: a quantitative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35066388" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The importance of drug titration in the management of patients with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15301575" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical pharmacokinetics of levetiracetam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8784217" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Lamotrigine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21205698" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20105139" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Tracking epilepsy with an electronic diary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17998482" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Seizure occurrence: precipitants and prediction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20060785" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Triggers and techniques in termination of partial seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22652423" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Seizure diaries for clinical research and practice: limitations and future prospects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23642342" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18397299" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6423336" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10749516" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Is there a role for therapeutic drug monitoring of new anticonvulsants?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23640503" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10691121" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32983615" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical utility of therapeutic drug monitoring of antiepileptic drugs: Systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31714640" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33950522" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Seizure freedom and plasma levels of newer generation antiseizure medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/383353" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical pharmacokinetics of phenytoin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effective levetiracetam doses and serum concentrations: age effects
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17381438" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/376307" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Sodium valproate, serum level and clinical effect in epilepsy: a controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6810648" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical and pharmacokinetic observations on sodium valproate - a 5-year follow-up study in 100 children with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15576287" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Therapeutic drug monitoring of old and newer anti-epileptic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9108642" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pharmacokinetics of valproic acid in patients with juvenile myoclonic epilepsy on monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9200763" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9577998" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15452293" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10515178" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7710545" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15955935" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36255131" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Seizure detection based on wearable devices: A review of device, mechanism, and algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35545836" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Automated seizure detection with noninvasive wearable devices: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31168498" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The utility of an automated and ambulatory device for detecting and differentiating epileptic and psychogenic non-epileptic seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32852091" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A new era in electroencephalographic monitoring? Subscalp devices for ultra-long-term recordings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Seizure forecasting and detection with wearable devices and subcutaneous EEG-A practical seizure gauge
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29609075" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The prevalence rates of medication adherence and factors influencing adherence to antiepileptic drugs in children with epilepsy: A systematic review and meta analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27781263" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A review of medication adherence in people with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19028602" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18031549" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18363527" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Comparison of drug adherence rates among patients with seven different medical conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18565827" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25252007" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Nonadherence to treatment causing acute hospitalizations in people with epilepsy: an observational, prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36512930" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Determinants of medication adherence in people with epilepsy: A multicenter, cross-sectional survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34462911" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Antiseizure medication adherence trajectories in Medicare beneficiaries with newly treated epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30980675" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Nonadherence to treatment regimens in epilepsy from the patient's perspective and predisposing factors: Differences between intentional and unintentional lack of adherence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26923477" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35483203" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Risk factors and consequences of self-discontinuation of treatment by patients with newly diagnosed epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33089492" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26414343" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A randomized controlled multimodal behavioral intervention trial for improving antiepileptic drug adherence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19864187" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Enhancing antiepileptic drug adherence: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19010447" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A telephone-based self-management program for people with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11971127" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Staged approach to epilepsy management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14706729" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36869855" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Should substitution monotherapy or combination therapy be used after failure of the first antiseizure medication? Observations from a 30-year cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33236785" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Starting a new anti-seizure medication in drug-resistant epilepsy: Add-on or substitute?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27330454" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : AES Position Statement on Generic Substitution of Antiepileptic Drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26099048" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Potential Clinical and Economic Impact of Switching Branded Medications to Generics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11524462" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Buy some today: can generics be safely substituted for brand-name drugs?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33426641" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33426641" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33426641" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28654954" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26201987" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33303376" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Widespread skeptic attitudes among people with epilepsy toward generic antiseizure drugs - A Swedish survey study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17346246" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27371490" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Nonadherence to antiepileptic drugs in Germany: A retrospective, population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34273105" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Physicians' attitudes toward generic substitutions of antiseizure drugs in epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34273105" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Physicians' attitudes toward generic substitutions of antiseizure drugs in epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20329806" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33444987" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Manufacturer switch of anti-seizure drugs may not increase the risk of seizure recurrence in Children: A nationwide study of prescription data in Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18616554" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19615948" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Association between antiepileptic drug switching and epilepsy-related events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19558250" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effects of antiepileptic drug substitutions on epileptic events requiring acute care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18695164" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26987080" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20631693" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Refilling and switching of antiepileptic drugs and seizure-related events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27683844" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
